VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in ...

VNRX READ THE FULL VNRX RESEARCH REPORT RECENT EVENTS Nu.Q Discover to be Utilized in a Human Clinical Study On March 4, 2025, VolitionRx (NYSE:VNRX) made a significant milestone announcement that, ...

VolitionRx (VNRX) announces the results of a study which shows that an automated Nu.Q Cancer immunoassay test in development detected a range ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of Volition's new lung cancer primer, "Lung Cancer: Hope of a Brighter Tomorrow ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces first patient enrollment in a clinical study evaluating the company's proprietary Nu.Q® Cancer ...

Saber CEO Matthew Karch, whose company used to be part of Embracer alongside Volition, explains what happened to the defunct ...

Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21 ...

VolitionRx (VNRX) announced the expansion of its Nu.Q Vet Cancer Test supply agreement with Fujifilm Vet Systems in Japan, to include ...